Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

CAR T Cell Exhaustion but Not Ex Vivo Cytotoxicity Is Predictive of Patient Clinical Response: An Interim Analysis of ACIT001/EXC002, a Phase Ib/II Trial of Decentralized Production of CAR T Cells for Treatment of Relapsed/Refractory Aggressive NHL and ALL

Charles Yin, Bindu Thapa, Carina Debes-Marun, Zack Breckenridge, Irwindeep Sandhu, Faisal Khan, Michael P. Chu

Blood (2023) 142 (Supplement 1): 2092.

https://doi.org/10.1182/blood-2023-187663

Published: 2023

Journal Articles

Alberta Cellular and Immunotherapy (ACIT) 001, Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Michael P. Chu, Zack M. Breckenridge, Andrew Daly, Mona Shafey, Victor A. Lewis, Sunil J. Desai, Peng Wang, Joseph Brandwein, Peter Duggan, Beverly Wilson, Bindu Thapa, Carina Debes-Marun, Irwindeep Sandhu

Blood (2022) 140 (Supplement 1): 7466–7467.

https://doi.org/10.1182/blood-2022-165887

Published: 2022

Journal Articles

Predicting Response of CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL) in ACIT001/EXC002, a Phase Ib Clinical Trial

Bindu Thapa, Carina Debes-Marun, Zack M. Breckenridge, Irwindeep Sandhu, Andrew Daly, Faisal Khan, Michael P. Chu

Blood (2022) 140 (Supplement 1): 12681–12682.

https://doi.org/10.1182/blood-2022-165930

Published: 2022